RecruitingPhase 2NCT06873516
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
Sponsor
Evommune, Inc.
Enrollment
160 participants
Start Date
Mar 20, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
- Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
- Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
Exclusion Criteria4
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
- Use of certain medications.
- History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
- Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEVO756
Dose 1
DRUGEVO756
Dose 2
DRUGEVO756
Dose 3
DRUGPlacebo control
Placebo control
Locations(53)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06873516
Related Trials
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT0567745165 locations
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT0725639220 locations
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT075409101 location
Remibrutinib in Real-world Clinical Practice
NCT073583641 location
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
NCT073161141 location